EDMONTON, Dec. 20 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA) and Paladin Labs Inc. (TSX: PLB) announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.
"Voclera™ was discovered by Isotechnika and has been in development since the late 1990's. This submission is the culmination of almost 15 years of discovery and development into a novel, next generation calcineurin inhibitor," states Dr. Robert Foster, President and CEO of Isotechnika Pharma Inc. "We believe Voclera™ offers a unique new treatment that is both safe and effective in treating patients with psoriasis, a very debilitating disease."
"VocleraTM is an innovative product that will provide an alternative treatment for psoriasis for Canadians." said Jonathan Ross Goodman, President and CEO of Paladin Labs.
Paladin acquired the Canadian commercial rights for VocleraTM from Isotechnika in June, 2009. Isotechnika will receive royalties on any sales of Voclera™ in Canada.
Isotechnika continues to develop voclosporin for use in prevention of organ rejection in kidney transplant recipients for the global marketplace.
About Isotechnika Pharma Inc.
Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of immunomodulating therapeutics that are designed to offer advantages over other currently available treatments. There is a significant unmet medical need in the treatment of both solid organ transplantation and autoimmune disease. It is estimated that the market potential will be $3 billion annually in sales for calcineurin inhibitors such as voclosporin in 2010.
About Paladin Labs
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies.
We seek Safe Harbor.
For further information: For further information: